Positive Outcomes from the DELTA TEEN Trial
LEO Pharma A/S has recently announced impressive results from the DELTA TEEN trial, a significant milestone in dermatology aimed at treating adolescents suffering from moderate to severe Chronic Hand Eczema (CHE). This pivotal phase 3 clinical trial explored the efficacy of Anzupgo® (delgocitinib) cream, a topical treatment leveraging a pan-Janus kinase (JAK) inhibitor, specifically designed for young patients aged 12-17 who haven't found relief through traditional topical corticosteroids.
Significance of the Trial
The DELTA TEEN trial is remarkable as it marks the fifth successful phase 3 study for Anzupgo, meeting both primary and key secondary endpoints. This accomplishment reinforces the findings from earlier trials within the DELTA program. This latest research expands LEO Pharma’s commitment to addressing the needs of adolescents who often face challenges in managing their CHE, a condition that lacks approved treatment options for this age group.
Impact on Adolescents
Adolescents with CHE face profound effects on their quality of life. Research indicates that the condition can hinder psychosocial well-being, adversely affect academic performance, and disrupt recreational activities. Professor Sonja Molin, an esteemed Academic Dermatologist at Charite Universitätsmedizin Berlin, highlights the urgency of understanding CHE in adolescents to better support this vulnerable group. The DELTA TEEN trial has shed light on this need, emphasizing how severe CHE directly impacts these young individuals.
Trial Results and Safety Profile
After 16 weeks of treatment, the trial reported a statistically significant improvement in CHE symptoms among participants using Anzupgo compared to those using a cream vehicle. Notably, the treatment’s safety profile was consistent with prior pivotal trials, indicating that Anzupgo is not only effective but also safe for young users. LEO Pharma's CEO, Christophe Bourdon, conveyed optimism regarding these findings, underscoring the company's mission to extend care to more individuals impacted by debilitating skin conditions.
Regulatory Position and Future Plans
Currently, Anzupgo is approved for adults across several regions, including the European Union, United Kingdom, and the United Arab Emirates. LEO Pharma is actively investigating its availability in other markets, specifically the United States, where adolescents are in desperate need of treatment protocols that suit their specific needs.
In-depth Understanding of Chronic Hand Eczema
Chronic Hand Eczema is characterized by persistent symptoms lasting longer than three months or recurrent episodes throughout the year. It is the most prevalent skin condition affecting the hands, demonstrating a notable prevalence rate, with many cases evolving into chronic forms. The disorder manifests with symptoms such as itchiness, skin inflammation, and physical discomfort, which can significantly hinder daily activities and diminish quality of life.
LEO Pharma's Commitment
LEO Pharma remains devoted to advancing treatment options for various skin conditions, including chronic hand eczema. As a global leader in dermatology, the company’s collaborative efforts with health professionals ensure that innovative therapies reach those who need them most. The results from the DELTA TEEN trial will be submitted for scientific presentation and publication, adding to the growing body of evidence supporting Anzupgo's efficacy.
Frequently Asked Questions
What is the DELTA TEEN trial about?
The DELTA TEEN trial investigates the use of Anzupgo® cream in treating adolescents suffering from moderate to severe Chronic Hand Eczema (CHE).
What are the primary results of the trial?
The trial reported a significant improvement in CHE symptoms after 16 weeks in adolescents treated with Anzupgo compared to the control group.
Who conducted the DELTA TEEN trial?
LEO Pharma A/S, a renowned leader in medical dermatology, conducted the DELTA TEEN trial.
Is Anzupgo® cream safe?
Yes, the safety profile of Anzupgo has been consistent with previous studies, indicating its safety for use in young people.
When will the results of the trial be available?
Detailed results are planned for submission for scientific presentation and publication, contributing to the ongoing discourse regarding CHE treatments.
